Ajay333 Posted - 10/25/24

@MasterShorts20 did you also see the troth with $ISEE and $TSLA 😂

The_Titan_Traders Posted - 2 months ago

$ICU $ISEE $SMMT $SPY $TNON Compliance PR from GLMD .. let’s double ✈️✈️

The_Titan_Traders Posted - 2 months ago

$SMMT $TNON $ICU $ISEE $SPY Next up GLMD don’t sleep on me

The_Titan_Traders Posted - 2 months ago

Next big idea GLMD I gave $SMMT at 1.20 and it’s currently trading over 30.00 I gave $TNON under 2.00 and it just went over 100.00 a share Friday. I gave $ICU under 1.00 and it’s now trading over 5.00 I gave $ISEE around 14.00 and even lower and it’s now trading over 40.00 https://x.com/tt_stocks_/status/1835349173551366480?s=46

ALATOM0369 Posted - 08/28/24

@TheUrbanFarmer @AnchorMB Astellas bought $ISEE ( Opus own some rights ) for $6B.

NVDAMillionaire Posted - 08/22/24

$ISEE IVERIC bio, Inc. (ISEE): Promising Ophthalmology Pipeline Overshadowed by Mounting Losses http://beyondspx.com/2024/08/04/iveric-bio-inc-isee-promising-ophthalmology-pipeline-overshadowed-by-mounting-losses/

The_Titan_Traders Posted - 3 months ago

$ISEE lmaooooooo 😂😂😂😂😂😂

geroscience Posted - 6 months ago

@oldwisetrader @dreinherz1 I agree with your sentiment but I don't think you were being serious about the buyout right? Seeing so many here jumping up and down like monkeys hoping for a buyout for a micro-cap biotech like $LCTX is not only incredibly short-sighted but also gives a sense that one does not really understand why you would invest in biotech at all. Why would you take all this risk for a potential BO premium that is always significantly constrained...? Although a BO is a 'positive' I don't think that should ever be the primary reason for investing in an early clinical stage biotech. The greatest value creation will come from Ph2 and/or Ph3 data showing that the product will be first and or best in class for a major debilitating disease of unmet need. We already have $APLS and $ISEE as examples in this space for how fundamental mature clinical data is for valuation.

TickrTalk0007 Posted - 7 months ago

$MSFT incredile how the stock has 4x in 4yrs….I left MSFT and kept all my stock. $MSFT $BTC $ISEE $APLS and $GME changed my life forever and possibly my kids life too (assuming i dont blow through all my money 😆) gratitude to the stock market and a boozy breakfast..peace✌

StocksBill Posted - 7 months ago

$ISEE

geroscience Posted - 8 months ago

@traderstatusquo92 @snosrap @Fedex11 I'm a clinician with relevant background and aspiring scientist - I agree it's still quite early. However I think with OpRegen so far being able to show GA reversal, something you'll never see in an RCT control arm, will enable smaller and shorter trials compared to what $APLS or $ISEE needed to generate evidence to support approval. I believe it has a decent shot at an accelerated approval pathway, probably via a Ph2b/Ph3a. Btw we have a retina surgeon here @retinachris who is a fellow OpRegen enthusiast.

Kashking03 Posted - 02/24/24

$OCUL..as posted on Twitter by @semodough $OCUL big checks were written for $OCUL - why - because Pravin U. Dugel, MD, Becomes Executive Chair of $OCUL - ask anyone who knew $ISEE well about him 👍- or if your fortunate enough ask one of these funds -Pravin U. Dugel, MD - game changer for $OCUL going forward

geroscience Posted - 9 months ago

$LCTX $APLS $ISEE Prof Vavvas has strong opinions on complement inhibition, but I didn't realise that one of the largest ophthalmology hospitals in the US doesn't use either drug at all? Honestly find that hard to believe given the massive launch that Apellis has had.

JeremyFalmouth Posted - 12/22/23

$OCUL interesting to see Deep Track take an ~8% stake in $OCUL. They were also large owners of $ISEE at the time of the buyout this year. New OCUL board member Adrienne Graves was chairman of the board at ISEE at time of buyout.

Futureview Posted - 11 months ago

$ALDX Is $ALDX the next $ISEE, maybe.

fin_researcher Posted - 11/30/23

$ISEE Investors of $ISEE may have reasons to suspect that the pricing terms of the M&A transaction are unfair and that the Company BoD breached fiduciary duties to shareholders. To claim compensation: https://11thestate.com/cases/isee-mna-case

Futureview Posted - 11/29/23

$RDHL This one acting very similar to $ISEE in 2019, so NOT a short.

Quantumup Posted - 1 year ago

Goldman Sachs initiated $APLS Buy/$74 est $3.9B Syfovre WW Peak Sales KOL suggests retinal vasculitis@ 0.01% acceptable; 2Y P3 $ALPMY | $ISEE Izervay data at #AAO23 underwhelmed KOLs /positions Syfovre as the more compelling Tx in GA; anticipates an inflection in Syfovre uptake (furthered by a permanent J-Code effective October 1).

TrendyChart Posted - 10/27/23

Upcoming Earnings Report: $ISEE IVERIC bio will be reporting on 11/06/2023 at 7:00AM | Do you believe in the potential for strong or weak earnings performance?

fin_researcher Posted - 1 year ago

Affected by the $ISEE stock drop? There might be a way to recover your losses: https://11thestate.com/cases/isee-mna-case

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $ISEE IVERIC bio will be reporting on 11/02/2023 at 7:00AM | What's your outlook on this stock's earnings?

Ablidy Posted - 1 year ago

$LCTX $ISEE

geroscience Posted - 1 year ago

$LCTX Remember the cherry-picked post-hoc analysis for $ISEE Iveric's GA drug showing a lower probability of losing 15 letters? The actual vision data on BCVA (and low luminance BCVA, another dimension of visual acuity that can be more severely affected in GA AMD) was no effect at 12 months: +0.38 letters for BCVA and -2.06 for LL-BCVA, both were not statistically nor clinically significant. Another way of understanding this is if you re-analyse the data by looking at the "probability of losing 5 letters", the "probability of losing 10 letters", the "probability of losing 15 letters", and etc...eventually one of these subgroups might favour your drug over sham - choosing which one to PR is easy for the company. This was also not 'pre-specified' (i.e. subgroup was identified before the trial started), and even if it were it would only be hypothesis generating. The saying "when you torture the data long enough it will confess" reflects this. https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-vision-loss-reduction-data-geographic

Nobanksallowed1500 Posted - 1 year ago

$ISEE

SupremeBoxLogo Posted - 08/23/23

$ISEE why can't we pass 40??? 😞

blackboxlabel Posted - 08/22/23

$APLS by show of hands, how many here took their $ISEE Merger payout and got into $APLS for another rocket?

Kjbobo Posted - 1 year ago

@sambrinton $ISEE was approved a week early. Your hypothesis cannot have much bearing because dates are set at least a year prior and randomly submitted applications by companies. Plus go study GRTX application, they had data wanting in safety…that’s a big deal. Haven’t looked into MESO yet. Applications are completely mutually exclusive….no pattern here

sambrinton Posted - 1 year ago

$OTLK All the following were approved… coincidentally all scheduled in the same week (I believe one may have been received early) $DCTH $NBIX $REGN $ISEE $RNVC

SupremeBoxLogo Posted - 1 year ago

$ISEE I saw this at 5 during covid and was to scared to buy FML!!!! 😭😭😭